10. Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54(1):34-44. 11. Sajjadi E, et al. Improving HER2 testing reproducibility in...
目前,HER2 低表 达乳腺癌的生物学特征尚不十分明确,HER2 低表达与 HER2 零表达患者预后以及传统治疗 反应差异亦不明确。该研究旨在明确 HER2 低表达与 HER2 零表达早期乳腺癌(eBC)患者 新辅助化疗(NAC)后的化疗敏感性和长期预后。 研...
Medical charts of 155 patients with breast cancer were reviewed for IHC and HER2 status, sites of metastases, total dose and fraction size of radiotherapy for brain metastasis,age and coure of the disease. Sample size was determined by statistical analysis according to previos studies. We ...
human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). 2024 ASCO.
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
[4] Véronique Diéras, Elise Deluche, Amélie Lusque, et al. Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY). SABCS 2021; Abstract PD8-02. ...
58, 59, 60, 61, 62, 63 The wide range of reported concordance rates between IHC and FISH assessment of HER2 status in breast cancer reflects, at least in part, the wide variation in methodology, instrumentation, and experience of the laboratories performing the testing. The sensitivity and ...
phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAI...
2.Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020; 54(1): 34-44. 3.Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol ...
Biologics: Targets & Therapy Dovepress open access to scientific and medical research Open Access Full Text Article HER2 breast cancer therapies: a review review Conleth G Murphy Shanu Modi Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY,...